4568 DAIICHI SANKYO explanation
- Prime Market
- TOPIX Core30
- JPX Nikkei Index 400
- Daiichi Pharmaceutical and Sankyo merged in 2005
- Strength in oncology and therapeutic drugs
- Strength in therapeutic technology called Antibody-Drug Conjugate (ADC), which specifically targets cancer cells and is characterized by its ability to suppress side effects and provide therapeutic effects.
- After concentrated investment in ADC, shift to a profit structure centered on new drugs
- Main product Olmertan→decline in sales, Prasugrel→decline in sales, Edoxaban→increase in sales, new main product Enhertu, a HER2 antibody-drug conjugate (ADC) for the treatment of breast cancer and gastric cancer, sales increase after its launch in Japan, US and Europe
Fiscal period
Mar.
4568 DAIICHI SANKYO Sales/Profit
Fiscal year ending March 2024
Sales：1601.6 billion yen（＋25.3%）
Operating income：211.5 billion yen（＋75.5%）
Ordinary profit：201 billion yen（＋84.1%）
